While not intended to replace the Amyloid, Tau, Neurodegeneration framework for AD diagnosis, we suggest that elevated PKM levels could indicate a more vulnerable group of patients in the early stages of AD, driven by a shift in glycolytic metabolism. Here, MAPT is linked to Alzheimer disease.